

Dr. Jorge Gallardo Ballart announces his intention to retire from his positions of President of the Board of Directors and Board member of Almirall

- **The resignation will be effective as of the end of the General Shareholders Meeting of Almirall, S.A. that will take place next 6 May 2022**
- **The Board of Directors has appointed Mr. Carlos Gallardo Piqué, current Vice-President of the Board, as President of the Board of Directors of Almirall from 6 May 2022.**
- **Nomination of Carlos Gallardo demonstrates commitment of the family to Almirall's future**

Almirall, S.A. (ALM) in accordance with the Stock Exchange Act, communicates the following:

Dr. Jorge Gallardo Ballart has announced in the Board of Directors' session on Friday 18th February, his intention to retire from his positions of Chairman of the Board of Directors and Board member with effect as of the end of the General Shareholders Meeting of Almirall, S.A. that will take place next 6 May 2022. In light of this decision, which has been carefully planned, the Board of Directors has appointed **Mr. Carlos Gallardo Piqué, current Vice-President of the Board, as President of the Board of Directors of Almirall** with effect from the end of the aforementioned General Shareholders Meeting. Mr. Carlos Gallardo has accepted his nomination.

Carlos has broad international healthcare experience. He started his pharmaceutical career in Pfizer prior to joining Almirall where he held positions of increasing seniority over nearly 10 years. Since leaving Almirall as General Manager of the UK and Ireland in 2013, Carlos has served as a member of Almirall's Board of Directors. In addition, he has established a successful career as a venture capitalist investing in digital health. He is the founder and CEO of CG Health Ventures where he invests in and builds digital health companies that match technology and talent to solve for challenges in healthcare. He serves on a number of boards of promising early stage digital health and health technology companies. Carlos holds an MS in industrial Engineering from the Universitat Politècnica de Catalunya and an MBA from Stanford University's Graduate School of Business.

Mr. Carlos Gallardo said: *"I am very pleased that I will assume this new role as **Chairman of Almirall and I'll keep working to bring the company to the next level as a Medical Dermatology leader.** Almirall is poised for growth and it is exciting to be part of this amazing journey. I am looking forward to working with the management team, the employees and Board of Directors in bringing innovative products in Medical Dermatology to improve the quality of patients' lives and grow the company going forward."*

The Board of Directors wishes to thank Dr. Jorge Gallardo for his immense contribution to Almirall. For over 50 years he has committed himself to creating one of Spain's most successful R&D based companies and has led the company with great distinction.

Dr. Jorge Gallardo stated: *"It has been a great privilege and pleasure to lead Almirall. We have had major successes and faced many challenges. I believe the company now has an exciting future ahead of it and that we have in place the management team and Board of Directors who can deliver this. I wish Carlos much success in his new role and in this new chapter of the company."*

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient's needs through science to improve their lives. Our Noble Purpose is at the core of our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life". We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange and is a member of the IBEX35 (ticker: ALM). Throughout its 79-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, with about 1,800 employees. Total revenues in 2021 were 836.5 million euros.

For more information, please visit [almirall.com](https://www.almirall.com)

Media contact:

Tinkle
Laura Blázquez
lblazquez@tinkle.es
Phone: (+34) 600 430 581

Investors' Relations contact

Almirall
Pablo Divasson del Fraile
pablo.divasson@almirall.com
Phone: (+34) 93 291 3087

Corporate Communications contact:

Almirall
Ester Riu
ester.riu@almirall.com
Phone: (+34) 671 580 438

Legal warning

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law.